Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Non-Current Liabilities: 2016-2025

Historic Other Non-Current Liabilities for Cytokinetics (CYTK) over the last 8 years, with Sep 2025 value amounting to $1.6 million.

  • Cytokinetics' Other Non-Current Liabilities was N/A to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $186,000 for FY2023, which is 82.18% down from last year.
  • As of Q3 2025, Cytokinetics' Other Non-Current Liabilities stood at $1.6 million, which was down 20.00% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Other Non-Current Liabilities peaked at $174.8 million during Q3 2021, and registered a low of $2,000 during Q1 2024.
  • Over the past 3 years, Cytokinetics' median Other Non-Current Liabilities value was $731,000 (recorded in 2023), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Cytokinetics' Other Non-Current Liabilities slumped by 99.76% in 2024, and later surged by 140,950.00% in 2025.
  • Quarterly analysis of 5 years shows Cytokinetics' Other Non-Current Liabilities stood at $4.5 million in 2021, then slumped by 76.58% to $1.0 million in 2022, then plummeted by 82.18% to $186,000 in 2023, then crashed by 99.76% to $2,000 in 2024, then soared by 140,950.00% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $2.0 million for Q2 2025, and $2.8 million during Q1 2025.